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VEGF-A activity is tightly regulated by ligand and receptor availability. Here we investigate the 
physiological function of heterodimers between VEGF receptor-1 (VEGFR-1; Flt-1) and VEGFR-2 
(KDR; Flk-1) (VEGFR1 − 2) in endothelial cells with a synthetic ligand that binds specifically to 
VEGFR1 − 2. The dimeric ligand comprises one VEGFR-2-specific monomer (VEGF-E) and a 
VEGFR-1-specific monomer (PlGF-1). Here we show that VEGFR1 − 2 activation mediates VEGFR 
phosphorylation, endothelial cell migration, sustained in vitro tube formation and vasorelaxation 
via the nitric oxide pathway. VEGFR1 − 2 activation does not mediate proliferation or elicit 
endothelial tissue factor production, confirming that these functions are controlled by VEGFR-2 
homodimers. We further demonstrate that activation of VEGFR1 − 2 inhibits VEGF-A-induced 
prostacyclin release, phosphorylation of ERK1/2 mAP kinase and mobilization of intracellular 
calcium from primary endothelial cells. These findings indicate that VEGFR-1 subunits modulate 
VEGF activity predominantly by forming heterodimer receptors with VEGFR-2 subunits and 
such heterodimers regulate endothelial cell homeostasis. 
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Vascular endothelial growth factor-A (VEGF-A), a multi-functional cytokine induced by hypoxic stress1, initiates the assembly of endothelial cells into new blood vessels, a 
process known as angiogenesis, via the activation of two receptor 
tyrosine kinases (RTKs), VEGF receptor-1 (VEGFR-1; Flt-1) and 
VEGFR-2 (KDR; Flk-1)2.
VEGF-A levels must be maintained within a narrow concentra-
tion range to ensure proper cardiovascular development and sur-
vival of the embryo3–5. The effects of VEGF-A can be deleterious if 
uncontrolled. Excess VEGF-A increases leakiness of blood vessels, 
which can cause severe oedema, loss of limb and death in animals6. 
Overexpression of VEGF-A in skeletal muscle causes hemangiomas 
(vascular tumours)7–9. By contrast, reduced VEGF-A activity in 
preeclampsia10, due to increased production of soluble VEGFR-1 
(sFlt-1)11, decreases angiogenesis12.
The varied functional activities of VEGF-A necessitate several 
regulatory mechanisms. In addition to sFlt-1 controlling VEGF 
activity13, membrane-bound VEGFR-1 homomeric receptor 
negatively regulates VEGFR-2-mediated endothelial cell prolif-
eration14–17 and tumour growth18. VEGFR-1 can transactivate 
VEGFR-2 (ref. 19) and an absolute requirement for VEGF recep-
tor subtype interaction exists during the development of different 
blood vessels in the zebrafish embryo20. Heteromerization of recep-
tor subunits is commonly observed for G-protein-coupled receptors 
and in RTK systems21,22. Heteromerization has been identified in 
the platelet-derived growth factor (PDGF)23 and epidermal growth 
factor (EGF)24,25 systems. Moreover, the EGF receptor subunit 
heterodimerizes with the PDGF-β-receptor subunit in unstimulated 
cells and is required for PDGF-mediated ERK1/2 phosphoryla-
tion26,27. The role of heterodimer receptors within the structurally 
related VEGF RTK system is ill-defined. Pre-assembled heterodimer 
receptors of VEGFR-2 and VEGFR-3 subunits have been isolated 
from primary lymphatic endothelial cells28,29 and detected in situ 
on angiogenic sprouts30. Heterodimerization between VEGFR-1 
and VEGFR-2 subunits (VEGFR1 − 2) has been detected in cell-free 
systems13 and in endothelial cell lines19,31–33. A computational 
model of VEGF receptor subunit dimerization concluded that a ten-
fold excess of one VEGF receptor subunit would result in minimal 
homodimerization of the less abundant receptor34. On the endothe-
lial cell surface, subunits of VEGFR-1 are up to tenfold less abun-
dant than those of VEGFR-2 (refs 35,36). This observation implies 
that the normal physiological state for VEGFR-1 subunits within 
the endothelium may be as part of heterodimers with VEGFR-2, 
and that VEGFR-1 in homodimer form may be relatively rare.
Extensive elucidation of VEGF receptor homodimeric-specific 
function has been possible owing to the existence of VEGF fam-
ily ligands that act selectively on the individual receptor homodim-
ers. VEGF-B and PlGF only bind to VEGFR-1, whereas VEGF-E, a 
non-mammalian viral protein, is a selective agonist for VEGFR-2. 
The native forms of VEGF-C and VEGF-D are VEGFR-3-specific. 
In vivo, VEGFR1 − 2 is activated by VEGF-A and the VEGF-A:PlGF-1 
heterodimer, but these ligands also simultaneously activate VEGF 
homodimeric receptors. Currently, no natural ligands are known 
that exclusively activate VEGFR1 − 2 without activating VEGFR-1 
homodimers. Therefore, dissection of VEGFR1 − 2 heterodimer- 
specific function has been challenging. Receptor subunit knock-
down and use of cell lines expressing specific receptors indicate that 
prostacyclin release33 and biphasic calcium induction32 is likely to 
be the result of VEGFR1 − 2 activation.
To investigate the function of VEGFR1 − 2 in endothelial cells, 
we have generated a novel, VEGFR1 − 2-specific ligand (VEGF-E:
PlGF-1), comprising one monomer of VEGFR-2-specific ligand 
(VEGF-E) and one monomer of PlGF-1, a specific ligand for 
VEGFR-1. We show that the heterodimer mediates responses previ-
ously shown to involve VEGFR-1 homodimers and negatively regu-
lates some VEGFR-2-mediated functions. Thus, VEGFR-1 subunits 
seem to regulate VEGF activity predominantly by forming het-
erodimer receptors with VEGFR-2 subunits to maintain endothe-
lial cell homeostasis. Receptor nomenclature in this manuscript 
follows the recommendations from Ferre and co-workers37. 
A ‘receptor’ is defined as the minimal functional, signal-transducing 
unit and, for RTKs, this normally comprises two subunits. There-
fore, a ‘homomer/homodimer receptor’ is the minimal functional 
unit comprised of two or more of the same subunits that are not 
functional on their own.
Results
VEGFR-1 and VEGFR-2 form heterodimers in endothelial cells. 
Heterodimerization between VEGFR-1 and VEGFR-2 subunits in 
preassembled complexes has been identified in cell-free systems13 
and in porcine32, bovine33 and murine19 endothelial cell lines. We 
confirmed VEGF receptor subunit heterodimerization in porcine 
aortic endothelial cells (PAEC) overexpressing human VEGFR-1 
and VEGFR-2 (PAER-1:R-2), by immunoprecipitation (Fig. 1a; 
Supplementary Fig. S1 for full-length blot). To date, evidence for 
VEGFR1 − 2 heterodimers in primary human endothelial cells has 
been lacking. Using the immunoprecipitation procedure optimized 
with the PAEC we successfully demonstrated that VEGFR-1 and 
VEGFR-2 subunits do heterodimerize in an immortalized human 
endothelial cell line (HMEC-1) and in primary human endothelial 
cells (HUVEC) (Fig. 1b). In addition, VEGFR-2 could be detected 
in VEGFR-1 immunoprecipitates (Fig. 1c) and co-localization of 
the two receptors in HUVEC was shown by confocal microscopy 
(Fig. 1d). Enzyme-linked immunosorbent assay (ELISA) further 
confirmed the presence of preassembled VEGFR1 − 2 heterodimers 
in human endothelial cells (Fig. 1e) and in the mouse liver, lung and 
kidney (Fig. 1f).
Production and purification of a VEGFR1 − 2-specific ligand. 
To characterize the function of the VEGFR1 − 2 heterodimer, we 
engineered a dimeric ligand that exclusively binds to this receptor. 
The ligand was produced using the insect cell-baculovirus system 
and comprises one monomer of VEGFR-2-specific VEGF-E and 
one monomer of His-Tagged, VEGFR-1-specific, human PlGF-1. 
VEGF-E is a viral protein, identified in a number of strains of the 
orf virus, which has the ability to specifically bind to and activate 
VEGFR-2 (ref. 38). The VEGF-E isoform used, in this study, was 
isolated from the D1701 strain39 and was engineered to contain the 
VEGF-A-heparin-binding domain40. This protein binds to both 
heparin and neuropilin-1 like VEGF-A40. Purification of the novel 
recombinant heterodimeric ligand was achieved by sequential appli-
cation of the medium to Ni-NTA and Heparin-Sepharose columns. 
The antibodies against VEGF-E and PlGF did not cross-react and 
the two proteins migrated differently (PlGF as two bands at 21 kDa 
and 22 kDa and VEGF-E at 23 kDa; Fig. 2a). Both proteins were 
expressed after simultaneous infection of the same cells with both 
viruses (Fig. 2b) and ELISA demonstrated heterodimerization of 
VEGF-E subunits with those of PlGF-1 after the infection (Fig. 2c). 
Samples of the purified proteins of PlGF-1, VEGF-E:PlGF-1 and 
VEGF-E were run adjacently on SDS–PAGE under reduced and 
non-reduced conditions to ascertain protein size and reactivity 
with the PlGF and VEGF-E antibodies. Silver staining showed that 
the heterodimer preparation was ~95% pure (Fig. 2d). Under non-
reducing conditions, the novel ligand migrated to an intermediate 
distance between PlGF-1 and VEGF-E at 43 kDa (Fig. 2d) and it 
reacted with antibodies against PlGF-1 and VEGF-E (Fig. 2d), con-
firming the purification of the heterodimeric ligand. To assess the 
binding capacity of the novel ligand to endothelial cells, PAER-1: 
R-2 were incubated with VEGF-E:PlGF-1 and binding detected 
using an anti-His-Tag antibody by fluorescence-activated cell 
sorting (FACS). Endothelial cells express PlGF, so the anti-His-Tag 
antibody was used to distinguish endogenous cell surface PlGF from 
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the novel ligand. The presence of VEGF-E:PlGF-1 was demonstrated 
on the cell surface of PAER-1:R-2 (Fig. 2e, bottom right), but not 
on PAEC, which lack VEGF receptors (Fig. 2e top left), PAER-1 
(Fig. 2e, top right) or PAER-2 (Fig. 2e, bottom left), demonstrat-
ing that VEGF-E:PlGF-1 specifically binds to the VEGFR1 − 2  
heterodimer receptor.
VEGF-E:PlGF-1 induces VEGFR-2 and ERK1/2 phosphorylation. 
To assess whether the VEGF-E:PlGF-1 ligand increases VEGFR1 − 2 
heterodimers to levels above those already preassembled, lysates of 
HUVEC stimulated with VEGF-E:PlGF-1 were immunoprecipi-
tated with anti-VEGFR-2 and immunoblotted with anti-VEGFR-1 
(Fig. 3a), or subjected to the human VEGFR1 − 2 ELISA (Fig. 3b). 
No increase in VEGFR1 − 2 was detected after addition of VEGF-E:
PlGF-1 in either assay. It is possible that our assays were not sensi-
tive enough to detect an increase in heterodimerization. However, 
these findings support the computational model of VEGF recep-
tor dimerization, which states that when an excess of one receptor 
subunit is present, most of the less abundant receptor subunit will 
be present as preassembled heterodimers with it34.
To assess whether the novel ligand could induce receptor 
phosphorylation, PAER-1:R-2 and HUVEC were stimulated with 
VEGF-A, VEGF-E and VEGF-E:PlGF-1. Lysates were immuno-
precipitated with anti-VEGFR-2, or anti-VEGFR-1 and immunoblotted 
for phosphorylated tyrosine residues. Tyrosine phosphorylation of 
VEGFR-2 was detected after stimulation with VEGF-A, VEGF-E 
and VEGF-E:PlGF-1 in PAER-1:R-2 and in HUVEC (Fig. 3c,d). 
Stimulation of HUVEC with equimolar concentrations of VEGF-A 
and VEGF-E induced strong phosphorylation of ERK1/2 MAPK, 
whereas VEGF-E:PlGF-1 only induced a weak ERK1/2 phospho-
rylation (Fig. 3d). VEGF-E:PlGF-1 could not induce VEGFR-2 
phosphorylation in PAER-2 cells (Fig. 3e) confirming the absence 
of contaminating VEGF-E homodimers in the ligand preparation 
and indicating that the presence of both receptors is required for 
the signalling activity of VEGF-E:PlGF-1. The PAER-1:R-2 cell 
line was produced by stably transfecting PAER-2 with human 
VEGFR-1, thus PAER-2 are the parent cells of PAER-1:R-2 cells. 
However, when equal protein concentrations of lysates were probed 
for total VEGFR-2, VEGFR-2 levels were found to be lower in 
PAER-2 cells compared with PAER-1:R-2 cells (Fig. 3e). The 
decreased expression of VEGFR-2 in PAER-2 cells was confirmed 
in different batches of the cells by western blotting (Supplementary 
Fig. S2A) and ELISA for human VEGFR-2 (Supplementary Fig. S2B). 
These interesting findings suggest that VEGFR-1 stabilizes 
VEGFR-2 in the cell. It is likely to be a structural feature of 
VEGFR-1 that stabilizes VEGFR-2 as mutation of VEGFR-1 tyro-
sine 1213, which is critical for VEGFR-1 function, did not affect 
VEGFR-2 levels in PAER-1:R-2 cells (Supplementary Fig. S2B). 
In addition, mutation of this tyrosine had no effect on the level of 
VEGFR-1 (Supplementary Fig. S2C) or heterodimerization within 
PAEC containing both receptors (Supplementary Fig. S2D). In 
addition, densitometric analysis indicated that phosphorylation 
of VEGFR-2 was greater in cells lacking VEGFR-1 (Fig. 3f). Short 
interfering RNA (siRNA)-mediated knockdown of VEGFR-1 in 
HUVEC (knockdown verified by western blotting; Fig. 3g) caused 
a big increase in VEGFR-2 phosphorylation (Fig. 3g). Interestingly, 
ERK1/2 MAPK phosphorylation was comparable to siRNA control-
transfected samples, but this was likely due to the stimulation time 
point being too short. Knockdown of either VEGFR-1 or VEGFR-2 
(Supplementary Fig. S3A for ELISA verifying VEGFR-2 knock-
down) inhibited the ability of VEGF-E:PlGF-1 to induce VEGFR-2 
and ERK1/2 phosphorylation (Fig. 3g).
Showing changes in the phosphorylation status of VEGFR-1 
is particularly difficult41,42. We attempted to ascertain VEGFR-1 
phosphorylation status following VEGF-A or PlGF-1 or VEGF-E: 
PlGF-1 stimulation of PAER-1:R-2. No increase in VEGFR-1 tyrosine 
ed
1
***
***
**
0.5
VE
G
FR
1-
2h
et
er
od
im
er
iza
tio
n
O
D 
(45
0–
54
0n
m
) n
orm
ali
ze
d 
to
 to
ta
l p
ro
te
in
0
HU
VE
C
HM
EC
PA
EC
PA
ER
-1
PA
ER
-2
PA
ER
-1/
–2
hV
EG
FR
-2
hV
EG
FR
-1
DAPI
VEGFR-2 VEGFR-1
MERGE
ba c
PA
ER
1:
R
2
Ly
sa
te
 b
ef
or
e 
IP Lysate
after IPIP
R
Ig
G
αR
2
R
Ig
G
αR
2
IB: VEGFR-1180
kDa
180
kDa
Lysate
Lysate
IB: VEGFR-1
H
UV
EC
H
M
EC
PA
ER
1:
R
2
H
UV
EC
H
M
EC
H
UV
EC
H
M
EC
IP: VEGFR-2
IP: VEGFR-1
IB:VEGFR-2
H
UV
EC
PA
E-
R
1:
R
2
H
UV
EC
H
UV
EC
230
210
kDa P
AE
-
R
1:
R
2
PA
E-
R
1:
R
2
IB: VEGFR-2230
210
IB: VEGFR-2230
210
IB:VEGFR-1180
f
0.1
0.05
0.15
LIV
ER
LU
NG
KID
NE
Y
m
VE
GF
R-1
m
VE
GF
R-2
0
IP: RIgG
IP: MlgG
VE
G
FR
1-
2h
et
er
od
im
er
iza
tio
n
O
D 
(45
0–
54
0n
m
) n
orm
ali
ze
d 
to
 to
ta
l p
ro
te
in
Figure 1 | VEGFR1 − 2 heterodimerization in human endothelial cells. Lysates of (a) PAER-1 cells, and (b) HmEC-1 and HuVEC cells were immuno-
precipitated with anti-VEGFR-2 or rabbit IgG and Western-blotted for VEGFR-1 or VEGFR-2. (c) PAER-1:R-2 cells and HuVEC were immunoprecipitated 
with anti-VEGFR-1 or mouse IgG and western-blotted for VEGFR-1 or VEGFR-2. (d) Confocal microscopy showing a representative image of VEGFR-1  
co-localized with VEGFR-2, in HuVEC. scale bar, 20 µm. (e) VEGFR1 − 2 heterodimerization was assayed in cell lysates by ELIsA. (f) VEGFR1 − 2 
heterodimerization was assayed in lysates from mouse organs. Results are expressed as mean ( + s.e.m.) of at least three independent experiments. 
**P < 0.01 versus PAER-2, ***P < 0.001 versus PAER-2.
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phosphorylation was detected by either immunoprecipitation or 
VEGFR-1 phospho-tyrosine ELISA.
Neuropilins have no role in VEGF-E:PlGF-1-induced signalling. 
The heparin-binding domain of VEGF confers the ability to inter-
act with two co-receptors; neuropilin-1 and -2 (NRP-1 and NRP-2). 
Although, VEGF cannot induce neuropilin phosphorylation or sig-
nalling, neuropilins have been shown to associate with the VEGF 
receptors43. This is reported to augment the functional response to 
VEGF in endothelial cells43. To ascertain whether neuropilins have 
any role in heterodimer receptor function, we used siRNA to knock-
down neuropilin-1 and neuropilin-2 in HUVEC and then stimulated 
with the ligand. Neuropilin-1 knockdown had no effect on VEGFR-2 
phosphorylation after VEGF-A or VEGF-E:PLGF-1 administration 
(Fig. 3g) and knockdown of neuropilin-1 or neuropilin-2 had no 
effect on ERK1/2 phosphorylation (Fig. 3h). This suggests neuro-
pilins are not having a major role for these signalling functions. 
(Verification of neuropilin-1 and neuropilin-2 knockdown can be 
seen in Supplementary Fig. 3c,d). Whether neuropilins are involved 
at a functional level warrants further enquiry.
Ligand and receptor dynamics. To assess cellular binding and 
trafficking of VEGF-E:PlGF-1, HUVEC treated with the ligand for 
2.5–120 min. were stained with the anti-VEGF-E antibody with-
out permeabilization. Confocal microscopy analysis demonstrated 
that VEGF-E:PlGF-1 bound to the cell but was undetectable by 
30–60 min (Fig. 4a). Following 15 min of stimulation, VEGF-E:
PlGF-1 was detected within the cell indicating internalization of 
the ligand (Fig. 4b). Interestingly, the staining pattern was strikingly 
different between cells stimulated with VEGF-E and those stimu-
lated with VEGF-E:PlGF-1. VEGF-E seemed to be predominantly 
located in the nucleus, whereas VEGF-E:PlGF-1 was diffusely 
distributed throughout the intracellular compartment (Fig. 4b).
HUVEC were treated with VEGF-A, VEGF-E and VEGF-E:
PlGF-1, and the distribution of the receptors evaluated using anti-
bodies raised against the amino-termini of VEGFR-1 and VEGFR-2. 
VEGFR-1 expression remained stable at the cell surface through-
out the stimulation period (Fig. 4c). By contrast, VEGFR-2 rapidly 
disappeared from the cell surface after stimulation with VEGF-E 
(Fig. 4c), whereas VEGFR-2 levels following stimulation with 
VEGF-A and VEGF-E:PlGF-1, which bind to VEGFR1 − 2 remained 
at the cell surface (Fig. 4c), further supporting to our earlier findings 
that the activation of VEGFR-1 can stabilize VEGFR-2 levels.
Functional consequences of VEGFR1 − 2 activation. Existing 
research using ligands specific for VEGFR-1 or VEGFR-2 homo-
meric receptors and cell lines expressing only a single receptor 
subunit type demonstrates that VEGF-A-mediated endothelial cell 
migration16,42, and induction of VEGFR-1 promoter activity and 
tissue factor release44, are VEGFR-2-mediated functions. However, 
the limitation of these tools is that they cannot fully delineate the 
contribution of VEGFR1 − 2 to these functions. Use of VEGF-E:
PlGF-1 in a modified Boyden chamber assay demonstrated that 
VEGFR1 − 2 activation is involved in the migration of human pri-
mary endothelial cells (Fig. 5a). VEGF-E:PlGF-1 could not induce 
migration of PAER-2 (Fig. 5b) confirming the absence of VEGF-E 
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contamination in the purified fraction. VEGF-E:PlGF-1 induced 
activity of a VEGFR-1 promoter luciferase reporter construct in 
cells containing both VEGFR-1 and VEGFR-2 subunits, but not 
in cells only expressing VEGFR-2 (Fig. 5c). VEGF-E:PlGF-1 also 
caused release of sVEGFR-1 from HUVEC (Fig. 5d), demonstrating 
the VEGFR1 − 2 signal results in a regulatory function.
Capillary-like tube formation on growth factor-reduced Matrigel 
requires endothelial cell differentiation and survival. HUVEC were 
seeded on matrigel and stimulated with VEGF ligands for 18 h. 
VEGF-E:PlGF-1 significantly induced in vitro tube formation to 
similar levels as that observed with VEGF-A and VEGF-E (Fig. 5e,f) 
suggesting that VEGFR1 − 2 heterodimer signalling is important for 
angiogenesis. VEGF-A induces endothelial cell proliferation as a 
direct result of VEGFR-2-mediated ERK1/2 MAPK phosphoryla-
tion45. Stimulation of HUVEC with VEGF-A and VEGF-E resulted 
in a significant increase in proliferation (Fig. 5g) consistent with the 
observed strong ERK1/2 phosphorylation (Fig. 3d,g). By contrast, 
VEGF-E:PlGF-1 induced only weak ERK1/2 phosphorylation 
(Fig. 3d,g) and did not induce cell proliferation (Fig. 5g), indicating 
that VEGFR-2 homodimer activation is required for the VEGF-
mediated proliferative response.
Tissue factor expression and subsequent coagulation has been 
attributed to VEGFR-2 (ref. 44). VEGF-E:PlGF-1 did not induce 
tissue factor expression, confirming the VEGFR-2 specificity of this 
response (Fig. 5h).
VEGF-E:PlGF-1 modulates vessel reactivity. An important 
function of VEGF-A is the regulation of vascular tone. After pre-
contraction, VEGF-E:PlGF-1, PlGF-1 and VEGF-A caused vasore-
laxation of arterial tissue (Fig. 6a). Relaxation could be abolished 
by co-incubation with l-NAME (Fig. 6b–d), confirming the role 
of endothelial-derived nitric oxide (NO) in vascular relaxation. 
Interestingly, activation of the VEGFR-2 homodimer by VEGF-E 
did not significantly alter vascular tone within the same concentra-
tion range as the other VEGF ligands (≤1 nM; Fig. 6a); providing 
evidence, for the first time, that VEGF-A-induced vasorelaxation 
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may depend on the VEGFR-1 homodimer and/or the VEGFR1 − 2 
heterodimer and that the VEGFR-1 homodimer is not involved.
It is well established that VEGF-A is important for the release of 
the vasodilator NO, and that NO is crucial for VEGF-A-mediated 
angiogenesis14,16,42,46,47. To ascertain whether VEGFR1 − 2 has 
a direct role in NO release, supernatants from VEGF-E:PlGF-1 
stimulated HUVEC were assayed for NO content, using a Sievers 
NOA 280 chemiluminescence analyser. VEGF-E:PlGF-1 induced 
NO release from HUVEC in a concentration-dependent manner 
(Fig. 7a) and stimulated eNOS activation as indicated by an increase 
in phosphorylation of eNOS at serine-1177 (Fig, 7b).
The VEGF-mediated release of prostacyclin from endothelial 
cells was previously attributed to VEGFR1 − 2 activation33. Consist-
ent with this report, stimulation of HUVEC with VEGF-E:PlGF-1 
induced a time-dependent and concentration-dependent increase 
in prostacyclin release as measured by the accumulation of its sta-
ble break-down product 6-keto PGF1α (Fig. 7c,d). However, our 
results also show that VEGF-A and VEGF-E promote much greater 
( > sixfold) 6-keto PGF1α release from HUVEC than VEGF-E:
PlGF-1 (Fig. 7e). Moreover, VEGF-A induced a tenfold increase in 
6-keto PGF1α release from PAER-2 cells while only eliciting a two-
fold release from PAER-1:R-2 cells (Fig. 7f). This finding suggests 
that VEGFR-2 homodimer activation is essential for strong VEGF-
A-induced prostacyclin release and the presence of VEGFR-1 
in PAER-2 cells negatively regulates prostacyclin release. To deter-
mine whether VEGFR1 − 2 antagonizes the action of the VEGFR-2 
homodimer receptor, we pre-treated HUVEC with VEGF-E:PlGF-1, 
stimulated them with either VEGF-A or VEGF-E and then assessed 
prostacyclin production (Fig. 8a). Interestingly, pre-incubation 
with VEGFR1 − 2 significantly reduced the ability of VEGF-A and 
VEGF-E to stimulate prostacyclin release, whereas PlGF-1 had no 
inhibitory effect. These data suggest that the inhibitory signal for 
this response is exclusively via VEGFR1 − 2.
Activation of VEGFR-2 mobilizes calcium from intracellular 
stores48, and evidence derived from cell lines expressing specific 
VEGF receptor subtypes indicated that the heterodimer mediated 
induction of calcium release in a biphasic manner32. In our study, 
VEGF-A caused a rapid, but transient calcium release in HUVEC 
(Fig. 8b). Pre-incubation of HUVEC with VEGF-E:PlGF-1 before 
VEGF-A addition delayed calcium mobilization in response to 
VEGF-A, and was followed by a slower and more-sustained release of 
calcium (Fig. 8b). Finally, pre-incubation of HUVEC with VEGF-E: 
PLGF-1 inhibited phosphorylation of ERK1/2 by VEGF-A and 
VEGF-E (Fig. 8c).
Discussion
This study demonstrates the existence of preassembled VEGFR1 − 2 
heterodimer receptors in human primary endothelial cells and 
animal tissues, and identifies their physiological function. Recent 
computer modelling of VEGF receptor subunit dimerization pre-
dicted that heterodimerization would be inevitable when cells 
express both VEGFR-1 and VEGFR-2 subunits34. Furthermore, 
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Figure 4 | Distribution of ligands and receptors in response to VEGF-E:PlGF-1. (a) Time course of VEGF-E:PlGF-1 stimulation of HuVEC, showing the 
presence of VEGF-E:PlGF-1 on the cell surface, detected with anti-VEGF-E using confocal microscopy. scale bar, 20 µm. (b) Intracellular localization of 
VEGFR-2 in HuVEC after stimulation with VEGF-E and VEGF-E:PlGF-1 for 15 min. scale bar, 40 µm. (c) Time course showing a comparison of VEGFR-1  
and VEGFR-2 distribution on the cell surface post-stimulation with VEGF-A, VEGF-E and VEGF-E:PlGF-1. scale bar, 20 µm.
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms1977
nATuRE CommunICATIons | 3:972 | DoI: 10.1038/ncomms1977 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
the model demonstrated that an excess of one VEGF receptor 
subunit would result in minimal homodimerization of the less 
abundant receptor subunit34. VEGFR-1 is known to be up to tenfold 
less abundant than VEGFR-2 on the endothelial cell surface35,36, 
implying that the majority of VEGFR-1 in endothelial cells exists 
in heterodimeric complexes with VEGFR-2. Our results show that 
VEGFR-1 predominantly modulates VEGF activity by forming 
heterodimers with VEGFR-2.
To investigate the function of VEGFR1 − 2 heterodimers in 
endothelial cells, we generated a selective ligand, comprising one 
monomer of VEGF-E (VEGFR-2-specific ligand) and one mono-
mer of PlGF-1 (VEGFR-1-specific ligand). Use of PAEC express-
ing VEGFR-1, VEGFR-2, or both receptor subunits, confirmed 
the specificity of the ligand for the heterodimer receptor in binding 
and function. In addition, the FACS binding assay discounted the 
possibility that the respective monomers of VEGF-E:PlGF-1 would 
bind to homodimer receptors and thereby stoichiometrically block 
the binding of other VEGF ligands.
The stimulation of murine lung capillary endothelial cells with 
VEGF-A was reported to increase the amount of VEGFR-1 asso-
ciating with VEGFR-2 (ref. 19). In this study, we were unable to 
demonstrate an increase in receptor heterodimerization following 
ligand stimulation. This suggests that maximal heterodimerization 
occurs under basal conditions providing further evidence that the 
majority of VEGFR-1 subunits exist as preformed heterodimers 
with VEGFR-2 in HUVEC, as predicted by MacGabhann and 
Popel’s computational model34. Although VEGF-A has a lower 
affinity for VEGFR-2 than VEGFR-1 (ref. 49), it is present in up to 
a tenfold excess of VEGFR-1. Therefore, VEGFR-1 subunits should 
exist as VEGFR1 − 2 heterodimers and preferentially bind VEGF-A 
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ahead of VEGFR-2 homodimers. We suggest that the presence 
of VEGFR-1-specific ligands such as PlGF and VEGF-B may be 
a mechanism for regulating VEGF receptor heterodimerization. 
Tyrosine phosphorylation of VEGFR-2, but not of VEGFR-1, could 
readily be detected after stimulation of VEGF-E:PlGF-1. Detect-
ing VEGFR-1 phosphorylation consistently under native condi-
tions is particularly difficult41,42. The fact that VEGF-E:PlGF-1 
induces a significant increase in VEGFR-2 phosphorylation without 
ba –5
–5
0
5
VEGF-E:PIGF-1
VEGF-E
PIGF-1
0
5
10
15
20
–12
VEGF-A
R
el
ax
at
io
n
(%
 pr
ec
on
str
ict
ion
)
R
el
ax
at
io
n
(%
 pr
ec
on
str
ict
ion
)
R
el
ax
at
io
n
(%
 pr
ec
on
str
ict
ion
)
R
el
ax
at
io
n
(%
 pr
ec
on
str
ict
ion
)
10
15
dc
log[ligand] (M)
–5
–5
–12 –11 –10 –9 –8
20
log[lVEGF-A] (M)
0
5
0
5
10
15
20
10
15
20
log[lVEGF-E:PlGF-1] (M)
–11 –10 –9 –8
–12
log[lPIGF-1] (M)
–11 –10 –9 –8 –12 –11 –10 –9 –8
Figure 6 | Vasorelaxation induced by VEGF ligands in isolated rat aorta. (a) VEGF-E:PlGF-1, PlGF-1 and VEGF-A, but not VEGF-E, cause vasorelaxation. 
The relaxation to (b) VEGF-A, (c) PlGF-1 and (d) VEGF-E:PlGF-1 is inhibited by nω-nitro-l-arginine methyl ester (l-nAmE; 200 µm) supporting a  
role for no in this response. Control (open circles), l-nAmE (black circles). Vessels are precontracted with EC80 phenylephrine and relaxation  
expressed as a percentage of the precontraction. Data points are means s.e.m. Results are expressed as mean ( + s.e.m.) of at least three  
independent experiments.
c100 ***
**
400ba
50 200
300
**
***
***
IB: eNOS
IB: p-eNOS (Ser1177) 140
140
Ve
h
VE
G
F-
A
VE
:P
L
PL
G
F-
1
VE
G
F-
E
0
Ve
hic
le
VE
GF
-A 10 20 50
To
ta
l N
O
 re
le
as
e
(nM
/w
ell
)
VEGF-E:PlGF-1 (ng ml–1) VEGF-E:PlGF-1 (ng ml–1)
06-
ke
to
 P
G
F 1
α
 
(pg
 m
l–1
) 
6-
ke
to
 P
G
F 1
α
 
(pg
 m
l–1
) 
6-
ke
to
 P
G
F 1
α
 
(pg
 m
l–1
) 
ed
200
300
400 Vehicle
VEGF-E:PlGF-1
1,000
1,500
Vehicle V-A 10 ng V-A 20 ng
0
100
Time (min)
**
***
***
***
***
**
*** ***
Ve
hic
le
VE
GF
-A
VE
GF
-E
0
500
PlG
F-1
VE
:Pl
100
10 20 30 40 50 60 70 80 90 10
0
11
00
0 10 20 30 40 50 60 70 80 9010
0
11
0
12
0
13
0
f
1,200
P<0.003
800
P<0.02
PA
ER
-2
PA
ER
-1:
R-
2
0
400
%
 In
cr
ea
se
 a
bo
ve
 c
on
tro
l
Figure 7 | VEGF-E:PlGF-1 causes NO and prostacyclin release. (a) Human umbilical vein endothelial cells (HuVEC) were rested overnight before 
stimulation with vehicle, VEGF-A or VEGF-E:PlGF-1 for 1 h and supernatant analysed for no content using a sievers noA 280 chemiluminescence 
analyzer. (b) HuVEC lysates were then subjected to sDs–PAGE and western-blotted with anti phospho-enos serine 1177 (p-enos (serine 1177)) and 
enos. (c) HuVEC were incubated with increasing concentrations of VEGF-E:PlGF-1 or (d), with VEGF-E:PlGF-1 (50 ng ml − 1) for increasing time periods 
and 6-keto PGF1α was assessed in the supernatants by ELIsA. **P < 0.01 versus vehicle. ***P < 0.001 versus vehicle. (e) Treatment with vehicle, VEGF-A, 
PlGF-1, VEGF-E and VEGF-E:PlGF-1 (VE:Pl). After 30 min, supernatant was collected and assayed for 6-keto-PGF1α by ELIsA. **P < 0.01 or ***P < 0.0001 
versus vehicle. (f) PAER-2 and PAER-1:R-2 were rested for 24 h before incubation with VEGF-A for 30 min. supernatant was collected and 6-keto PGF1α 
was assessed by ELIsA. Results are expressed as mean ( + s.e.m.) of at least three independent experiments.
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms1977
nATuRE CommunICATIons | 3:972 | DoI: 10.1038/ncomms1977 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
 binding to VEGFR-2 homodimers demonstrates that the VEGFR-2 
 subunit undergoes tyrosine phosphorylation when dimerized with 
a VEGFR-1 subunit.
To assess the physiological effect of the VEGF-E:PlGF-1 hetero-
dimer, we performed various in vitro assays with endothelial 
cells. The novel ligand mediated endothelial cell migration and 
VEGFR-1 promoter activity, and caused sustained in vitro tube for-
mation to an extent comparable with VEGF-A and VEGF-E. These 
results suggest a role for VEGFR1 − 2 in endothelial cell differentia-
tion and maintenance. VEGFR1 − 2 activation resulted in induction 
of ERK1/2 phosphorylation, but had no significant effect on cell 
proliferation, confirming previous findings that VEGF-A-induced 
proliferation is a VEGFR-2-mediated event41.
VEGF-A regulates vessel tone via NO production, which is 
dependent on eNOS activation. In addition, eNOS phosphorylation 
and NO release are crucial for VEGF-mediated angiogenesis16,50,51. 
VEGF-A, PlGF-1 and VEGF-E:PlGF-1 caused significant relaxation 
of vessels precontracted with phenylephrine, whereas activation of 
the VEGFR-2 homodimer, using VEGF-E, did not increase vessel 
relaxation. This provides the first evidence that VEGF-A-induced 
vasorelaxation depends on the VEGFR-1 homodimer and/or 
the VEGFR1 − 2 heterodimer, and does not require the VEGFR-2 
homodimer. Endothelial VEGFR1 − 2 activation also resulted in 
eNOS phosphorylation and NO release.
VEGF-A-induced permeability requires the release of prosta-
cyclin, an event initially attributed to VEGFR-2 homodimer action, 
because PlGF does not increase prostacyclin release52. However, use 
of VEGF-C and antisense knockdown of VEGF receptors led Neagoe 
and colleagues33 to propose that VEGF-A-induced prostacyclin 
release was a VEGFR1 − 2-specific phenomenon. This study shows 
that VEGF-E, which exclusively activates the VEGFR-2 homodimer, 
induces ~15-fold increase in prostacyclin release from HUVEC. 
This indicates that VEGFR-2 homodimerization per se, can cause 
prostacyclin release from endothelial cells, whereas the magnitude 
of the VEGF-E:PlGF-1-induced increase in prostacyclin release 
was only threefold. This clearly demonstrates that although prosta-
cyclin release can be mediated exclusively by the heterodimer 
receptor activation, it is predominantly a VEGFR-2 homodimer 
receptor function. Additionally, VEGF-A stimulation of PAER-2 
induced a tenfold rise in prostacyclin release, whereas only a two-
fold release was apparent after VEGF-A stimulation of PAER-1:R-2. 
This finding suggests that VEGFR-1 negatively regulates prostacyclin 
release from endothelial cells. The convoluted approach taken by 
Neagoe and colleagues33 to study VEGFR1 − 2 heterodimerization 
further illustrates the benefit of this specific ligand.
VEGF-A regulates its own bioactivity by a number of nega-
tive feedback systems; two examples are NO production14 and 
sVEGFR-1 release53. In this study, we have shown that both of these 
functions are positively mediated by VEGFR1 − 2 activation. Several 
groups have established that VEGFR-1 is a negative regulator of 
VEGFR-2-mediated endothelial and tumour cell proliferation14–18. 
Thus, we hypothesized that the overall function of VEGFR-1 form-
ing heterodimeric receptors with VEGFR-2 may be to negatively 
regulate VEGFR-2 homodimer function in endothelial cells. Pre-
incubation of HUVEC with VEGF-E:PlGF-1 abrogated VEGF-A 
and VEGF-E-mediated prostacyclin release, whereas preincubation 
with PlGF-1 had no effect. In addition, preincubation of cells with 
VEGF-E:PlGF-1 delayed the normally rapid and transient VEGF-
A-mediated mobilization of intracellular cellular calcium and the 
eventual rise in calcium entry was much slower, but more sustained. 
Rapid increases in intracellular calcium generally equate to release 
from intracellular stores, whereas slower rises in intracellular cal-
cium are due to influx from an extracellular source. The data suggest 
that VEGF-A alone, via VEGFR-2 can activate these intracellular 
stores. In contrast, VEGFR1 − 2 activation elicits an inhibitory signal 
that delays this release.
A subsequent dimension to receptor heterodimer function is the 
regulation of the activating ligand, be that VEGF-A or VEGF-A:
PlGF. For the endogenous heterodimeric ligand (VEGF-A:PlGF) to 
be produced, there must be co-expression of both proteins in the 
same cell. A highly relevant publication has demonstrated that when 
this does occur, in a mouse tumour model, branching angiogenesis 
persists and monocyte migration into the tumours is enhanced54, 
thus showing a biological relevance of the heterodimer ligand and 
receptor. However, the contribution of VEGF-A and/or VEGF-A:
PlGF to heterodimer receptor activation and cell function is likely to 
a 2,000
1,500
Vehicle
VEGF-E:PlGF-1
PlGF-1
500
1,000
6-
ke
to
 P
G
F 1
α
 
(pg
 m
l–1
) 
Ve
hic
le
VE
GF
-A
VE
GF
-E
0
b
1.1
1.2
Vehicle
VEGF-E:PlGF-1
VEGF-A
0.9
1.0
[C
a2
+ ] i 
F3
40
/F
38
0
0.8
0
Time (s)
50 100 150 200 250 300 350
c
kDa
Veh VA
– – – + + +
VE Veh VA VE
42
44 IB: p-ERK1/2
VEGF-E:PLGF-1
IB: β-actin42
Figure 8 | VEGF-E:PlGF-1 inhibits VEGF-A-induced prostacyclin, calcium release and phosphorylation of ERK1/2 in endothelial cells. (a) HuVEC 
were rested overnight before preincubation with PlGF-1 or VEGF-E:PlGF-1 for 30 min and subsequent treatment with vehicle, VEGF-A and VEGF-E. 
supernatants were collected and 6-keto PGF1α assessed by ELIsA. (b) HuVEC were preincubated with vehicle or VEGF-E:PlGF-1 for 30 min, before 
addition of VEGF-A. Intracellular calcium release was assessed using Fura-2 Am. (c) HuVEC were preincubated with vehicle or VEGF-E:PlGF-1 for  
30 min then stimulated with VEGF-A or VEGF-E for 15 min. radio immunoprecipitation assay lysates were subjected to sDs–PAGE and immunoblotting  
for phosphorylated ERK1/2. Results are expressed as mean ( + s.e.m.) of at least three independent experiments.
ARTICLE
0
nATuRE CommunICATIons | DoI: 10.1038/ncomms1977
nATuRE CommunICATIons | 3:972 | DoI: 10.1038/ncomms1977 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
be regulated in a complicated spatial and temporal manner, which 
warrants future in-depth study in in vivo systems.
In conclusion, data gathered using VEGF-E:PlGF-1 demon-
strate that VEGFR1 − 2 activation is functional in endothelial cells 
and that the heterodimer receptor serves as a negative regulator 
of the VEGFR-2 homodimer to regulate angiogenesis. This adds 
another layer of complexity to the regulation of VEGF-A func-
tion. It is possible that the low threshold homeostatic function of 
VEGF-A is achieved by the formation of the VEGFR1 − 2 heterodimer, 
whereas pro-angiogenic and proliferative function is mediated by 
VEGFR-2 homodimers. We conclude that heterodimerization 
between VEGFR-1 and VEGFR-2 subunits, negatively regulates both 
the signalling and cell response of the VEGFR-2 homodimer. This 
may be important for angiogenesis and endothelial cell homeostasis. 
If validated in vivo, this concept would be a dramatic paradigm shift 
in the current understanding of VEGF receptor biology. Future 
studies should establish whether this mechanism is apparent in vivo 
and if heterodimerization is dysregulated in pathologies.
Methods
Reagents and antibodies. Growth factors and receptors were purchased from 
RELIATech (Brauschweig, Germany). Mouse anti-VEGFR-1 (Flt-11) was pur-
chased from Sigma (Poole, UK). Mouse IgG, mouse anti-His-Tag, mouse anti-PY99 
and rabbit anti-VEGFR-2 (C-1158) were obtained from Autogen Bioclear (Calne, 
UK). Rabbit polyclonal antiobodies against ERK1/2, phospho-ERK1/2 (tyr 402/thr 
404), Akt, phospho-Akt (ser 463), endothelial nitric oxide synthase (eNOS), and 
phospho-eNOS (ser 1177) were obtained from NEB (Hitchin, UK). Mouse/goat 
anti-VEGFR-1 and VEGFR-2; and biotinylated goat anti-VEGFR-1, VEGFR-2 and 
phospho-tyrosine antibodies were purchased from R & D Systems (Abingdon, 
UK). Anti-PlGF55 (clone 172) and anti-VEGF-E39 were gifts from Dr Weich. 
MTT (3-(4,5-Dimethylthiazol–2-yl)-2,5-diphenyltetrazolium bromide) thiazolyl 
blue was purchased from Sigma-Aldrich (Poole, UK) and growth factor-reduced 
Matrigel obtained from Becton Dickinson (Oxford, UK). Sf21 insect cells, TC-100 
and Sf 900 II medium were purchased from Invitrogen (Paisley, UK).
Cell culture. HUVEC were isolated and cultured as described previously16. 
Experiments were performed on third or fourth passage HUVEC. Human dermal 
microvascular endothelial cells (HMEC-1), immortalized by transformation with 
the SV-40 large T-antigen, were a gift from Dr E. Ades, Centre for Disease Control, 
Atlanta, USA. The PAEC expressing human VEGFR-1 (PAER-1) or VEGFR-2 
(PAER-2) were maintained in medium supplemented with G418. PAER-1:R-2 were 
maintained in medium supplemented with zeocin. Sf 21 insect cells were expanded 
in spinner flasks in TC-100 medium supplemented with 5% FCS, maintained at 
27 °C and infected with baculoviruses in serum-free Sf 900 II medium.
Immunoprecipitation and western Blotting. PAER-1:R-2, HMEC-1 and HUVEC 
lysed in radio immunoprecipitation assay buffer were immunoprecipiated using 
rabbit anti-VEGFR-2 (C-1158) or mouse anti-VEGFR-1. Membranes were incu-
bated with mouse anti-PY99, mouse anti-VEGFR-1 (Flt-11), goat anti-VEGFR-1 or 
rabbit anti-VEGFR-2 (C-1158). After stimulations, HUVEC lysate was separated 
on SDS–PAGE and membranes probed with rabbit polyclonal antibodies, against 
signalling molecules, at 4 °C overnight. Supernatants from baculoviral infections 
were run on 15% gels and membranes probed with rabbit anti-PlGF-1 (1 in 100)  
or rabbit anti-VEGF-E (1 in 2,000). The same antibodies were used to detect PlGF 
and VEGF-E post purification.
ELISA assay. The ELISA for VEGFR1 − 2 used anti-VEGFR-1 capture antibodies 
against either, the human or mouse protein and biotinylated anti-VEGFR-2 detec-
tion antibodies (R&D Systems). The ELISA for VEGF-E:PlGF-1 heterodimers used 
an anti-His-Tag capture antibody, an anti-VEGF-E detection and a goat anti-rabbit 
HRP conjugate.
Phosphorylated VEGFR-2 was detected using a mouse anti-VEGFR-2 capture 
antibody and a biotinylated phospho-tyrosine detection antibody. The sVEGFR-1  
concentration in cell supernatants was determined as described previously12. 
VEGFR-2 was measured in cell lysates using the VEGFR-2 ECD DuoSet ELISA 
(R&D Systems). 6-keto PGF1α was measured in cell supernatants using the 6-keto 
PGF1α EIA kit (Biogenesis, Poole, UK).
Expression and purification of recombinant VEGF-E:PlGF-1. The VEGF-E 
isoform used was isolated from the D1701 strain39 and engineered to contain the 
VEGF-A-heparin-binding domain40. The cloning, expression and purification of 
6xHis-tagged PlGF-1 and heparin-binding VEGF-E using a baculoviral system has 
already been described40,55. To produce VEGF-E:PlGF-1, Sf 21 insect cells were 
infected with baculoviruses encoding VEGF-E and PlGF-1. Clarified supernatant 
was then applied to a nickel chelating column (Ni-NTA; Qiagen, Crawley, UK) and 
bound proteins eluted with imidazole. The fractions containing PlGF-1 homodim-
ers and VEGF-E:PlGF-1 heterodimers were identified by immunoblotting. VEGF-
E-positive fractions were pooled, dialysed, loaded on a Heparin-Sepharose column 
(HiTrap Heparin; GE Healthcare, Amersham, UK), and eluted with a sodium 
chloride gradient56. After immunoblotting fractions positive for both proteins  
were pooled, dialysed against PBS and used for in vitro experiments.
FACS analysis. PAEC were incubated with VEGF-E:PlGF-1 (0.5 µg per 106 cells ml − 1). 
Binding was detected using an anti-His-Tag and then a secondary FITC-conjugated 
anti-mouse. Flow cytometry was performed using a FACScan flow cytometer with 
CELLQuest software (Becton Dickinson, Oxford, UK) and the 488 nm argon laser. 
15,000 cells were collected from each sample. Data were acquired in a list mode 
and three parameters checked; forward scatter, side scatter and one fluorescence 
channel (FL-1).
siRNA transfection. HUVEC were electroporated with siRNA duplexes to 
VEGFR-1 (sense, 5′-UGAUGGCCUUACACUGAAAtt-3′; antisense, 5′-UUUCAG 
UGUAAGGCCAUCAtt-3′), VEGFR-2 (sense, 5′-GGAAAUCUCUUGCAAGCU 
Att-3′; antisense, 5′-UAGCUUGCAAGAGAUUUCCtt-3′), neuropilin-1 (sense, 
5′-GUAUACGGUUGCAAGAUAAtt-3′; antisense, 5′-UUAUCUUGCAACCG 
UAUACtt-3′), neuropilin-2 (sense, 5′-CCAGAAGAUUGUCCUCAACtt-3′;  
antisense, 5′-GUUGAGGACAAUCUUCUGGtt-3′) or universal control siRNA 
(Dharmacon) using the HUVEC kit II and AMAXA nucleofector (Lonza,  
Germany)53.
Real-time PCR. Total RNA of cultured cells was isolated using the total RNA 
Purification Kit (Norgen Biotek Corporation, Thorold, Canada) and 1 µg RNA 
was reverse-transcribed. Real-time PCR was performed for neuropilin-1 (sense 
5′-CGCTCCCGCCTGAACTACCCT-3′; antisense, 5′-TGAGGTGCGGGTGG 
AAGTGCC-3′), neuropilin-2 (sense GGTGCGGGAAGCCAGCCAGGA; anti-
sense GCCCCCAGGAGGACGCCCAGT) and β-actin57 using SYBR green and 
SensiMix (dT) DNA Kit (Quantace, London, UK) on a RotorGene 3000 (Corbett 
Research, Sydney, Australia). For each run, a standard curve was prepared along-
side the sample complementary DNAs. Relative neuropilin-1/2 mRNA expression 
was calculated from the ∆Ct values following normalization to β-actin levels. PCR 
products were run on 2% agarose gel to verify product size (neuropilin-1: 521 bp; 
neuropilin-2: 447 bp) and purity.
Immunofluorescence imaging. HUVEC were stimulated with growth factors  
and fixed with 4% (w/v) paraformaldehyde. To determine cell surface VEGFR-1 
and VEGFR-2 expression after stimulations, fixed cells were incubated with  
primary antibodies goat-anti-VEGFR-1 (R&D Systems; 1 in 10), rabbit- 
anti-VEGFR-2 (Cell Signaling; 1 in 20), respectively, then FITC-labelled anti-goat 
(Sigma; 1 in 200) and TRITC-labelled anti-rabbit secondary antibodies (Cell  
Signaling; 1 in 200). To determine VEGF-E trafficking in HUVECs after  
stimulation, cells permeabilized with ice-cold methanol were incubated with  
rabbit-anti-VEGF-E antibody (ReliaTECH) then TRITC-labelled anti-rabbit  
secondary antibody (Sigma). To determine VEGFR-1 and VEGFR-2 co- 
localization, permeabilized HUVEC were incubated with both goat anti- 
VEGFR-1 and rabbit anti-VEGFR-2 primary antibodies and detected with  
FITC-labelled anti-goat and TRITC-labelled anti-rabbit secondary antibodies. 
Cells were counterstained with DAPI, and viewed using a Zeiss LSM 510 confocal 
scanning microscope (Carl Zeiss, Jena, Germany). Images were analysed using 
LSM 510 software (version 2.3; Carl Zeiss).
In vitro migration. Chemotaxis experiments with HUVEC, HMEC, PAEC and 
PBMC were performed in a modified Boyden chamber16. Cells migrated towards 
growth factor gradients for 6 h through 8 µm PVP-free membranes. Membranes 
were then fixed in methanol, stained with Diff-Quik (Harleco, USA) and cell  
migration quantified by counting 8–10 fields of view at X10 magnification.
VEGFR-1 promoter reporter assay. PAER-1 and PAER-1:R-2 were transfected 
with a luciferase reporter construct containing ~1.3 kb. fragment of the human 
VEGFR-1 promoter using Exgen 500 (Fermentas, York, UK) before incubation 
with VEGF-A or VEGF-E:PlGF-1 and promoter activity determined with a  
luminometer.
Coagulation assay. Confluent HUVEC monolayers were stimulated with growth 
factors for 6 h, and a coagulation assay was performed and clotting times converted 
to tissue factor equivalents58.
In vitro tube formation assay. Formation of capillary-like structures on growth-
factor reduced Matrigel was determined, as previously described16.
MTT assay. Confluent HUVEC were rested overnight in medium containing  
5% FCS, then stimulated with growth factors for 96 h. MTT (5 mg ml − 1) was  
added and the cells incubated in the dark at 37 °C for 4 h. MTT was aspirated  
and reconstituted in dimethylsulphoxide. Optical density values were measured  
at 540 and 690 nm.
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Myography. All experiments were performed according to the Animals Scientific  
Procedures Act 1986 (U.K. Home Office)59. Briefly, adult male Wistar rats 
(250–400 g; Charles River, Margate, UK) were killed by cervical dislocation. The 
thoracic aorta was dissected free, cleaned and ~5 mm length sections mounted in 
a multi-myograph system (610M; Danish Myo Technology, Aarhus, Denmark) in 
Krebs buffer bubbled with 5% CO2/95% O2 at 37 °C. A baseline tension of 14.7 mN 
was gradually applied over 10 min and vessels were allowed to equilibrate for a 
further 30 min before challenge with 80 mM KCl to assess viability. Phenylephrine 
was used to precontract vessels to ~80% maximum contraction (EC80; ~0.2 µM) 
for each individual aortic ring. Following precontraction, cumulative concentration 
response curves to VEGF ligands (0.01–1 nM) were performed in separate vessel 
segments. Drugs were washed out and concentration response curves were repeated 
in the presence (20 min preincubation and presence throughout concentration 
response curve) of the nitric oxide synthase inhibitor Nω-Nitro-l-arginine methyl 
ester (l-NAME; 200 µM) and the cyclooxygenase inhibitor indomethacin (10 µM). 
The data from force transducers were processed by a MacLab/4e analog–digital 
converter and displayed through Chart software, version 3.4.3 (AD Instruments, 
Sussex, UK).
Analysis of NO release. Confluent HUVEC were incubated with growth factors 
in medium containing 0.2%. BSA, for 1 h at 37 °C. Total NO in the culture medium 
was assayed as nitrite, the stable breakdown product of NO, using a Sievers NO 
chemiluminescence analyzer (Analytix, Sunderland, UK).
Calcium imaging. HUVEC were grown to 90% confluency on gelatin-coated  
coverslips, and loaded with the calcium sensitive dye, Fura-2 AM (Molecular 
Probes, UK), for 30 min. After rinsing, growth factors were added and the  
change in calcium influx was dynamically assayed over a 2-min period.
Statistical analysis. All data are expressed as mean ± s.e.m. Statistical  
comparisons were performed using one-way ANOVA followed by the  
Student—Newman–Keuls test as appropriate. Statistical significance was  
set at a value of P < 0.05. 
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